{
    "clinical_study": {
        "@rank": "16497", 
        "acronym": "MOO", 
        "arm_group": [
            {
                "arm_group_label": "Oxytocin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Saline Nasal Spray", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to examine the effects of intranasal oxytocin administration on\n      social cognition in patients receiving methadone maintenance treatment (MMT), examine the\n      effects of intranasal oxytocin administration on opioid craving and on the subjective\n      effects of methadone, and examine the effects of intranasal oxytocin administration on\n      implicit preferences for drug-related and social stimuli in patients receiving MMT.\n\n      Hypotheses 1: Patients will perform better on measures of social cognition (including affect\n      recognition and recognition of sarcasm) after administration of oxytocin compared with\n      placebo.\n\n      Hypothesis 2: Patients will demonstrate lower craving for opioids and greater subjective\n      effects of methadone after administration of oxytocin compared with placebo.\n\n      Hypothesis 3: Patients will demonstrate increased implicit preferences for social stimuli\n      and decreased implicit preferences for drug related stimuli after administration of oxytocin\n      compared with placebo."
        }, 
        "brief_title": "Methadone Oxytocin Option", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Substance Abuse", 
            "Opioid Dependence", 
            "Methadone Treatment"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Opioid-Related Disorders", 
                "Substance-Related Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria for patients:\n\n          -  Primary diagnosis of opioid dependence according to DSM-IV TR\n\n          -  Opioid of choice be either heroin or oral opioid analgesics\n\n          -  Currently be on stable dose of methadone with no dose change in the last 14 days\n\n        Inclusion Criteria for healthy volunteers\n\n        -No diagnosis of mental disorder according to DSM-IV TR\n\n        Exclusion Criteria for patients and healthy volunteers:\n\n          -  Epilepsy\n\n          -  Current illicit drug use (within the past one month)\n\n          -  Current sever depression with suicidal thoughts and/or actions\n\n          -  Addiction to alcohol or drugs other than opiates, caffeine, or nicotine\n\n          -  Psychotic illness\n\n          -  Bipolar disorder\n\n          -  Brain trauma\n\n          -  Severe Neuropsychological disorder\n\n          -  Kidney Disease (i.e., kidney stones, recurrent bladder infections, or known kidney\n             failure)\n\n          -  Sensitivity to preservatives (in particular E216, E218, and chlorobutanol\n             hemihydrate)\n\n          -  Nasal obstruction, discharge, or bleeding\n\n          -  Cardiovascular problems (e.g., heart disease, history of heart attacks), high blood\n             pressure (hypertension)\n\n          -  Habitually drink large volumes of water"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728909", 
            "org_study_id": "0"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oxytocin", 
                "description": "40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.", 
                "intervention_name": "Oxytocin", 
                "intervention_type": "Drug", 
                "other_name": "Syntocinon"
            }, 
            {
                "arm_group_label": "Saline Nasal Spray", 
                "description": "40 IU of the saline nasal spray will be administered once at the beginning of the visit.", 
                "intervention_name": "Saline Nasal Spray", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methadone", 
                "Oxytocin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Oxytocin", 
            "Syntocinon", 
            "Social Cognition", 
            "Social Approach Behaviors"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94121"
                }, 
                "name": "San Francisco VA Medical Center"
            }, 
            "investigator": {
                "last_name": "Joshua Woolley, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of Intranasal Oxytocin on Social Cognition and Social Approach Behaviors in Opioid-dependent Patients Receiving Methadone Treatment", 
        "overall_contact": {
            "email": "sfvaoxytocinstudy@gmail.com", 
            "last_name": "Wanda Lai", 
            "phone": "415-340-2331"
        }, 
        "overall_official": {
            "affiliation": "University of California San Francisco, San Francisco Veterans Affairs Medical Center", 
            "last_name": "Joshua Woolley, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Participants will undergo computer tasks that measure social cognition, which include the TASIT, RMET, and  the IAT. The  TASIT measures the awareness of social inference, the RMET measures the ability to guess the emotions of others, and the IAT measures implicit associations.", 
            "measure": "Computerized Social Cognition Tasks", 
            "safety_issue": "No", 
            "time_frame": "Participants will complete 2 days of the study. These 2 days will be at least a week apart."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728909"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "Joshua Woolley", 
            "investigator_title": "Assistant Professor in Residence", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Participants are asked to rate their current symptoms and current craving levels and for different substances.", 
            "measure": "Craving Questionnaires", 
            "safety_issue": "No", 
            "time_frame": "Participants will complete 2 days of the study. These 2 days will be at least a week apart."
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": {
                "agency": "San Francisco Veterans Administration Medical Center", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}